RE:RE:Who's Selling?The merger has to either get done or get cancelled, in my opinion. This no man's land isn't helping anyone given current biotech sentiment. If the merger gets cancelled, expect a huge TRX rush back to about $1.70 and an obliteration of POZN. If when the merger goes through, I'd expect some pop with ARLZ followed by more doldrums until financials/BD/Yosprala. I expect another kick in the teeth with POZN reports its next quarterly results as they're ramping up staff for 2016, salaries that will not be offset by new revenues as well as dealing with other merger costs. We could very well be dead money until summer 2016 but that's ok if the return is what we think it is. Just gotta be patient .....